KCTD7抗体—艾普蒂

The KCTD7 antibody is a crucial tool in studying the potassium channel tetramerization domain-containing 7 (KCTD7) protein, which belongs to the KCTD family implicated in ubiquitination, transcriptional regulation, and ciliary function. KCTD7 is primarily expressed in the brain and is associated with neuronal lysosomal storage disorders. Mutations in the KCTD7 gene are linked to a rare autosomal recessive condition called progressive myoclonic epilepsy (PME) with neuronal ceroid lipofuscinosis (NCL), characterized by seizures, motor decline, and vision loss. Research suggests KCTD7 interacts with cullin-3 to form E3 ubiquitin ligase complexes, influencing protein degradation pathways. However, its exact molecular mechanisms remain under investigation. Antibodies targeting KCTD7 enable detection of protein expression, localization, and dysfunction in cellular and tissue models, aiding in understanding disease pathology. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore KCTD7's role in neurodegeneration and lysosomal regulation. Recent studies also highlight potential therapeutic applications, such as gene therapy or small-molecule interventions targeting KCTD7-related pathways. Despite progress, challenges persist in clarifying its tissue-specific functions and interactions, underscoring the need for validated, high-specificity KCTD7 antibodies in both basic and clinical research.